Abzyme Therapeutics is a privately held biopharmaceutical company that is harnessing the power of its proprietary antibody generation and optimization platform leveraged with the advantages of single-domain antibodies to develop novel potent immunotherapeutics. 

Abzyme Therapeutics welcomes investors who bring a wealth of experience in drug discovery and development and provide valuable strategic support to the company.